Results 271 to 280 of about 25,581,606 (307)
Some of the next articles are maybe not open access.
Advanced non-small cell lung cancer
Current Treatment Options in Oncology, 2001The treatment of advanced non-small cell lung cancer requires histologic proof of diagnosis, careful staging, and assessment of each patient's performance status and comorbidities. For patients with stage IIIB (pleural effusion) and stage IV disease who have a Cancer and Leukemia Group B performance status (PS) of 0 to 1, appropriate management ...
M J, Edelman, S L, Khanwani
openaire +2 more sources
Screening for Non-Small Cell Lung Cancer
Seminars in Oncology, 2005Lung cancer is the leading cause of cancer mortality and is usually discovered at an advanced stage, when treatment is generally not effective. Many researchers have investigated the value of screening for lung cancer, which would theoretically allow earlier detection and more effective treatment.
Rendell W, Ashton, James R, Jett
openaire +2 more sources
Angiogenesis in non-small cell lung cancer
Seminars in Thoracic and Cardiovascular Surgery, 2004Two processes are necessary for a tumor colony to grow and become invasive: angiogenesis and basement membrane degradation. Angiogenesis is the formation of new blood vessels from the endothelium of existing vasculature, in response to the metabolic demand of the tumor.
openaire +2 more sources
Necitumumab for non-small cell lung cancer
Expert Opinion on Biological Therapy, 2015Targeting the EGFR pathway is a rational approach to treat patients with advanced NSCLC. Necitumumab, a second-generation recombinant fully human immunoglobulin G1 monoclonal antibody directed against EGFR, has recently been assessed in combination with first-line cisplatin-based chemotherapy.This article reviews literature on necitumumab development ...
Laurent, Greillier +2 more
openaire +2 more sources
Surgery for non-small cell lung cancer
Lung Cancer, 2001Although never proven to be superior in a randomized trial, surgical resection remains the treatment of choice for early stage non-small cell lung cancer (NSCLC). In stages IA, IB, IIA, IIB and selected stages IIIA surgical treatment offers the best long-term prognosis when a complete resection can be performed.
openaire +3 more sources
Radiotherapy for non-small cell lung cancer
Lung Cancer, 2001This article shortly reviews the role of external-beam radiotherapy in the management of NSCLC with the focus on novel therapeutic approaches. The following applications of radiotherapy are addressed: definitive treatment in localized inoperable disease, radiotherapy as an adjunct to surgery (preoperative and postoperative), and palliative chest ...
openaire +2 more sources
Gefitinib in non-small cell lung cancer
Expert Opinion on Pharmacotherapy, 2005Gefitinib (Iressa), an orally-active tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR), is the first approved molecular-targeted drug for the management of patients with advanced non-small cell lung cancer (NSCLC). Two Phase II trials (IDEAL [Iressa Dose Evaluation in Advanced Lung Cancer]-1 and -2), evaluated the efficacy of ...
Kenji, Tamura, Masahiro, Fukuoka
openaire +2 more sources
Paclitaxel for non-small cell lung cancer
Expert Opinion on Pharmacotherapy, 2004Paclitaxel, a tubulin-binding agent, is widely used for the treatment of non-small cell lung cancer (NSCLC). The combination of paclitaxel and a platinum compound is an approved regimen for the treatment of advanced NSCLC. The dose-limiting toxicity of paclitaxel is myelosuppression when administered on a prolonged infusion schedule, whereas neuropathy
Sakkaraiappan, Ramalingam +1 more
openaire +2 more sources
Imaging of Non–Small Cell Lung Cancer
Radiologic Clinics of North America, 2005Radiologic evaluation is an important component of the clinical staging evaluation of lung cancer and can greatly influence whether the patient is treated with surgical resection, radiation therapy, chemotherapy, or a combination of these modalities. In addition to staging, the radiologic evaluation of the patient undergoing treatment and subsequent ...
Reginald F, Munden, John, Bruzzi
openaire +2 more sources

